Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Dexcom

Dow Jones Falls After Stock Market Sell-Off; JPMorgan Jumps On Upgrade; Tesla Extends Losses

The Dow Jones Industrial Average fell Tuesday, looking to rebound after Monday's stock market sell-off. JPMorgan jumped on a double upgrade.

Investors Business Daily

Dow Jones Dives On Fear Of More Rate Hikes Into 2023; Tesla Stock Skids On Production Cut Reports

Dow Jones futures were little changed ahead of Tuesday's open after the Dow Jones Industrial Average dived more than 480 points Monday.

Investors Business Daily

Dow Jones Sells Off After Economic Data; Tesla Skids On Plans To Cut Production

The Dow Jones Industrial Average fell Monday after key data. Tesla stock skidded on reports that Tesla plans to cut production in Shanghai.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Dow Jones Futures Fall In Resilient Market Rally; Tesla Stock Falls On Production Cut

Futures fell after the S&P 500 retook key levels last week. Oil prices rose. Tesla stock fell on China production cut reports.

Investors Business Daily

Stock Market Investing Action Plan: What Part Of November Don't You Understand?

A turnabout month left the market sitting on some nice gains. The next week's data might determine whether those gains hold.

Investors Business Daily

Dexcom Leads 5 Stocks Near Buy Points

Dexcom and other top stocks to watch this week combine strong technicals with generally solid fundamentals.

Investors Business Daily

Dow Jones Futures Rise: 5 Stocks Near Buy Points In Market Rally; Tesla FSD Beta Expands Widely

The S&P 500 still faces its 200-day line with key economic data looming. Tesla FSD Beta gets a wide release after TSLA stock jumped from bear market lows.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Dow Jones Futures: Apple Holds, Amazon Joins Megacap Meltdown; What To Do Now

Apple dipped after the iPhone giant topped views. Amazon crashed on guidance, joining the megacap earnings meltdown.

Investors Business Daily

This Is What Whales Are Betting On DexCom

Someone with a lot of money to spend has taken a bullish stance on DexCom (NASDAQ:DXCM). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Diabetes patients can now get ‘life-changing’ blood sugar gadget on the NHS

Cutting edge technology could be beginning of the end for people needing to draw blood several times a day to test their levels

Daily Mirror

Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022

Benzinga

The UK’s First Diabetic Giant Anteater Has Been Fitted With A Glucose Monitor

The first diabetic giant anteater in the United Kingdom has been fitted with a monitor to check its blood glucose levels – which is normally used on humans.

Zenger

Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years

DexCom (NASDAQ:DXCM) has outperformed the market over the past 15 years by 20.9% on an annualized basis producing an average annual return of 27.35%. Currently, DexCom has a market capitalization of $30.77 billion.

Benzinga

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $16,000 Today

DexCom (NASDAQ:DXCM) has outperformed the market over the past 5 years by 64.52% on an annualized basis producing an average annual return of 74.42%. Currently, DexCom has a market capitalization of $115.32 billion.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Elon Musk And Tesla Finally Get Good News In June

June is a month some S&P 500 investors would like to skip. But it's still a good month to stay engaged with stocks, especially Elon Musk's Tesla.

Benzinga

Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years

DexCom (NASDAQ:DXCM) has outperformed the market over the past 15 years by 22.06% on an annualized basis producing an average annual return of 28.95%. Currently, DexCom has a market capitalization of $29.24 billion.

Investors Business Daily

Dexcom Pops After Insulet Buyout Rumor Shakes Up Diabetes Stocks

Dexcom stock popped Tuesday after the diabetes devices company refuted rumors that it's in active negotiations to acquire any company.

Benzinga

What Are Whales Doing With DexCom

A whale with a lot of money to spend has taken a noticeably bearish stance on DexCom. Looking at options history for DexCom (NASDAQ:DXCM) we detected 25 strange trades.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

How The Rumored Dexcom-Insulet Marriage Could Rock The Entire Diabetes Space

Dexcom stock yo-yoed Wednesday after a Tuesday dive on rumors it's in talks to acquire insulin pump-maker Insulet in a major diabetes deal.

Benzinga

Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg

Dexcom Inc (NYSE:DXCM) is reportedly in talks to acquire medical-device company Insulet Corporation (NASDAQ: PODD) to create a giant in diabetes devices, according to people with knowledge of the matter. According to Bloomberg, talks between the companies are ongoing, and an agreement could be reached in the coming weeks. Discussions could still be delayed or fall…

Benzinga

DexCom Earnings Perspective: Return On Invested Capital

Pulled from Benzinga Pro data, DexCom (NASDAQ:DXCM) posted Q1 earnings of $97.30 million, an increase from Q4 of 601.55%. Sales dropped to $628.80 million, a 9.94% decrease between quarters.

Benzinga

If You Invested $1000 In DexCom 10 Years Ago, Here's How Much You Would Have Today

DexCom (NASDAQ:DXCM) has outperformed the market over the past 10 years by 32.66% on an annualized basis producing an average annual return of 44.4%. Currently, DexCom has a market capitalization of $39.95 billion.

Benzinga

Read Here Why Did This Analyst Cut DexCom's Price Target

Benzinga

Recap: DexCom Q1 Earnings

DexCom (NASDAQ:DXCM) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings DexCom missed estimated earnings by 38.46%, reporting an EPS of $0.32 versus an estimate of $0.52.

Investors Business Daily

Diabetes Giant Dexcom Snagged On Unexpectedly Low Profit, Sales Outlook

Dexcom stock dipped late Thursday after the diabetes devices company reported lighter-than-expected first-quarter profit.

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.